Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

XCOPRI DIN 02538806

Status: Approved
Holder: KNIGHT THERAPEUTICS INC.
Molecule: CENOBAMATE

Health Canada record

Active ingredient(s)CENOBAMATE 100 MG; CENOBAMATE 150 MG
Dosage formTablet; Kit
RouteOral
SchedulePRESCRIPTION
ClassHuman
ATCN03AX25 CENOBAMATE
Original market date
Current status date19-Dec-2025
SourceHealth Canada DPD

Establishment licence of the holder

Knight Therapeutics Inc. — licence 3-002350, currently licensed, last inspection rating C (2025-11-05).

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing CENOBAMATE

DINProductCompanyFormStrengthStatus
02538792XCOPRIKNIGHT THERAPEUTICS INC.Tablet; KitCENOBAMATE 150 MG; CENOBAMATE 200 MGApproved
02538652XCOPRIKNIGHT THERAPEUTICS INC.TabletCENOBAMATE 12.5 MGMarketed
02538660XCOPRIKNIGHT THERAPEUTICS INC.TabletCENOBAMATE 25 MGMarketed
02538725XCOPRIKNIGHT THERAPEUTICS INC.TabletCENOBAMATE 50 MGMarketed
02538733XCOPRIKNIGHT THERAPEUTICS INC.TabletCENOBAMATE 100 MGMarketed
02538741XCOPRIKNIGHT THERAPEUTICS INC.TabletCENOBAMATE 150 MGMarketed
02538768XCOPRIKNIGHT THERAPEUTICS INC.TabletCENOBAMATE 200 MGMarketed
02538776XCOPRIKNIGHT THERAPEUTICS INC.Kit; TabletCENOBAMATE 12.5 MG; CENOBAMATE 25 MGMarketed
02538784XCOPRIKNIGHT THERAPEUTICS INC.Kit; TabletCENOBAMATE 50 MG; CENOBAMATE 100 MGMarketed
02538814XCOPRIKNIGHT THERAPEUTICS INC.Tablet; KitCENOBAMATE 150 MG; CENOBAMATE 200 MGApproved

Notices of Compliance

NOCDateSubmissionReason
365812025-12-19New Drug Submission (NDS)Administrative: Change in product ownership
309702023-06-12New Drug Submission (NDS)

International API supply for CENOBAMATE

8 active FDA Drug Master Files.

Request a quote for XCOPRI

How to read a Canadian DIN record